|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,932.60 INR | -0.90% |
|
-0.15% | +12.38% |
| 12:36pm | India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease | RE |
| 07-15 | India's Sun Pharma wins South Africa approval to launch generic Ozempic | RE |
| Market Cap | 4,679B 48.56B 42.44B 39.25B 36.02B 68.17B 69.35B 468B 184B 2,285B 182B 178B 7,888B | P/E 2027 * |
35.6x | P/E 2028 * | 30.1x |
|---|---|---|---|---|---|
| Enterprise Value | 4,406B 45.72B 39.97B 36.96B 33.92B 64.19B 65.3B 441B 173B 2,151B 172B 168B 7,428B | EV / Sales 2027 * |
6.74x | EV / Sales 2028 * | 5.95x |
| Free-Float |
44.39% | Yield 2027 * |
0.81% | Yield 2028 * | 0.91% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.90% | ||
| 1 week | -0.15% | ||
| Current month | +3.76% | ||
| 1 month | +6.16% | ||
| 3 months | +15.34% | ||
| 6 months | +15.35% | ||
| Current year | +12.38% |
| 1 week | 1,910 |  | 1,962.7 |
| 1 month | 1,812.5 | | 1,962.7 |
| Current year | 1,583.7 | | 1,962.7 |
| 1 year | 1,548 | | 1,962.7 |
| 3 years | 1,063.85 | | 1,962.7 |
| 5 years | 672.55 | | 1,962.7 |
| 10 years | 312 | | 1,962.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.90% | -0.15% | +13.46% | +79.34% | 48.56B | |
| -0.23% | -1.65% | +65.14% | +112.03% | 35.65B | |
| -0.76% | -1.44% | -4.30% | +37.38% | 11.98B | |
| -0.88% | -0.62% | +16.38% | +89.65% | 11.95B | |
| +0.56% | +1.90% | +34.67% | +129.06% | 9.29B | |
| -0.50% | -0.66% | +18.56% | +37.57% | 6.95B | |
| +3.37% | -0.10% | +49.31% | -3.75% | 6.79B | |
| -2.25% | -2.08% | +0.40% | +218.27% | 6.7B | |
| +7.04% | +17.50% | -14.38% | +29.12% | 6.81B | |
| -0.97% | +2.11% | +22.72% | +138.54% | 4.48B | |
| Average | +0.45% | +1.47% | +20.19% | +86.72% | 14.91B | |
| Weighted average by Cap. | -0.12% | +0.69% | +26.23% | +87.70% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 654B 6.79B 5.93B 5.49B 5.04B 9.53B 9.7B 65.44B 25.71B 319B 25.49B 24.93B 1,103B | 729B 7.57B 6.62B 6.12B 5.61B 10.63B 10.81B 72.97B 28.66B 356B 28.43B 27.8B 1,230B |
| Net income | 133B 1.38B 1.2B 1.11B 1.02B 1.93B 1.97B 13.27B 5.21B 64.75B 5.17B 5.05B 224B | 157B 1.62B 1.42B 1.31B 1.21B 2.28B 2.32B 15.66B 6.15B 76.46B 6.1B 5.97B 264B |
| Net Debt | -273B -2.84B -2.48B -2.29B -2.1B -3.98B -4.05B -27.34B -10.74B -133B -10.65B -10.41B -461B | -341B -3.54B -3.1B -2.86B -2.63B -4.98B -5.06B -34.16B -13.42B -167B -13.31B -13.02B -576B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/07/26 | ₹1,932.60 | -0.90% | 2,475,664 |
| 16/07/26 | ₹1,950.10 | -0.07% | 1,396,189 |
| 15/07/26 | ₹1,951.50 | +0.46% | 2,283,494 |
| 14/07/26 | ₹1,942.60 | +1.10% | 2,822,124 |
| 13/07/26 | ₹1,921.40 | -0.73% | 1,573,176 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
